Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 November 2023 - 1:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 6, 2023
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark,
6 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s
board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to
publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares
issued by Novo Nordisk.
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated Person |
Christina Law |
2 |
Reason
for the notification |
|
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details
of the issuer |
|
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
|
|
|
|
4 |
Details
of the transaction(s) |
|
a) |
Description of the financial instrument, |
ADRs |
|
type of instrument, |
|
|
|
|
|
Identification code |
NVO |
b) |
Nature of the transaction |
Purchase of ADRs |
c) |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 683.35 |
600 ADRs |
|
|
|
|
DKK 681.96 |
600 ADRs |
|
|
|
|
DKK 677.32 |
100 ADRs |
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|
·
Aggregated volume |
1,300 ADRs |
|
·
Price |
DKK 886,920.28 |
e) |
Date of the transaction |
2023-11-03
|
f) |
Place of the transaction |
New
York Stock Exchange |
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com |
Elizabeth DeLuca (US)
+1 609 580 9868
edel@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg
Rode
+45 3075 5956
jrde@novonordisk.com |
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
|
|
Sina Meyer
+45 3079 6656
azey@novonordisk.com |
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Alle 1
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
www.novonordisk.com
CVR no: 24 25 67 90 |
|
|
Company announcement No 70 / 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 6, 2023 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024